A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Public ClinicalTrials.gov record NCT02998476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Study identification
- NCT ID
- NCT02998476
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2017
- Primary completion
- Feb 21, 2019
- Completion
- Feb 4, 2021
- Last update posted
- Aug 21, 2025
2017 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Arizona Oncology Associates, PC - HAL | Tempe | Arizona | 85284 | — |
| Sutter Gould Medical Foundation | Modesto | California | 95355 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Advanced Pharma CR, LLC | Miami | Florida | 33147 | — |
| Asclepes Research Centers | Weeki Wachee | Florida | 34607 | — |
| Advocate Medical Group Niles Milwaukee Ave | Niles | Illinois | 60714 | — |
| Indiana BMT | Beech Grove | Indiana | 46107 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| University of Kentucky Hospital | Lexington | Kentucky | 40536-0298 | — |
| St. Agnes Hospital | Baltimore | Maryland | 21229 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| St. John Hospital and Medical Center | Detroit | Michigan | 48236 | — |
| CHI Health - St. Francis Medical Center | Grand Island | Nebraska | 68802 | — |
| Summit Medical Group | Morristown | New Jersey | 07960 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901-1914 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Utah Cancer Specialists- Network | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02998476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02998476 live on ClinicalTrials.gov.